Get the Stockscreener App
37.64
3.04%
1.11
After Hours:
37.79
0.15
+0.40%
Sionna Therapeutics Inc stock is traded at $37.64, with a volume of 199.77K.
It is up +3.04% in the last 24 hours and up +3.58% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$36.53
Open:
$36.3
24h Volume:
199.77K
Relative Volume:
0.66
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.78%
1M Performance:
+3.58%
6M Performance:
+79.32%
1Y Performance:
+89.53%
1-Day Range:
$36.07
$38.86
1-Week Range:
$34.87
$38.91
52-Week Range:
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
37.64 | 1.63B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com India
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $84,237.30 in Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. (SION) Stock Analysis: Biotech’s Promising Prospects with 5.7% Upside Potential - DirectorsTalk Interviews
Sionna Therapeutics (SION) 10% owners sell $10 million in stock By Investing.com - Investing.com South Africa
Major Stake Unloaded in Sionna Therapeutics Sparks Fresh Market Buzz - TipRanks
Tpg Gp A, Llc Sells 250,000 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (SION) 10% owners sell $10 million in stock - Investing.com
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownHere's Why - MarketBeat
Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring a 7.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Sentiment: Should you avoid Sionna Therapeutics Inc stock right now - baoquankhu1.vn
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.1%Here's Why - MarketBeat
Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target - TipRanks
BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat
SION: Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026 - TradingView
SION: First-in-class NBD1 stabilizers target full CFTR correction, with pivotal data expected mid-2026 - TradingView — Track All Markets
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.1%Here's What Happened - MarketBeat
Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple - Yahoo Finance
Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study - MSN
Sionna Therapeutics, Inc. (SION) Stock Analysis: A 27.73% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Assessing Sionna Therapeutics (SION) Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio - Sahm
Market Recap: How Sionna Therapeutics Inc. stock compares to industry benchmarks2025 Sector Review & Trade Opportunity Analysis - Улправда
Is Sionna Therapeutics Inc. stock positioned for long term growthPortfolio Value Summary & Smart Money Movement Tracker - Улправда
Sionna Therapeutics (NASDAQ:SION) Trading Up 7.7%Here's Why - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 7.5%What's Next? - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Raymond James raises Sionna Therapeutics stock price target on CF drug potential - Investing.com Canada
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - AOL.com
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - The Motley Fool
Sionna Therapeutics Insider Sold Shares Worth $1,486,010, According to a Recent SEC Filing - marketscreener.com
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):